Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: shero who wrote (897)	12/18/1997 1:44:00 PM
From: EZLibra	Read Replies (2) \| Respond to of 3702

Whew! Blistering. When the settlement comes could you have the gang of three's options disgorged in to the company treasury? The board could grant them to the new CEO as performance options. Add in a percentage of their salarys and it would be a good compensation package. Now that would be good management. Back to the science; Human Genome Sciences (HGSI) just gained FDA approval to test its' first gene based drug in humans. MPIF-1 (myeloid progenitor inhibitory factor-1) temporary suppresses normal marrow cell division, thus protecting healthy bone marrow cells from the toxic effect of cancer drugs. The following from today's Washington Post, "If it allows you to triple the dose of some (cancer) drugs, that's probably good and it's possible it would be associated with an improved response rate', said Marc Lippman, director of Georgetown University's Lombardi Cancer Center. But no one knows yet whether higher chemotherapy doses would really cure many more cancers, he said, and organs other than marrow may not be able to tolerate such high doses." You don't suppose TCLN director Lippman is spreading the word on TNT do you?